Axsome Therapeutics financials
$186.14−4.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M | $50.0M | $0.00 | — | — | — | — | — |
| Gross profit | $591.0M | $352.4M | $244.5M | $44.8M | $0.00 | — | — | — | — | — |
| Gross margin | 92.6% | 91.4% | 90.4% | 89.6% | — | — | — | — | — | — |
| Operating income | -$166.8M | -$280.6M | -$231.8M | -$179.8M | -$124.7M | -$99.1M | -$67.2M | -$32.8M | -$27.2M | -$27.5M |
| Net income | -$183.2M | -$287.2M | -$239.2M | -$187.1M | -$130.4M | -$102.9M | -$68.3M | -$31.0M | -$28.9M | -$27.2M |
| Net margin | −28.7% | −74.5% | −88.4% | −374.0% | — | — | — | — | — | — |
| Diluted EPS | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.77 | $-2.01 | $-1.15 | $-1.27 | $-1.42 |
| EBITDA | -$159.9M | -$273.6M | -$225.0M | -$175.4M | -$124.6M | -$99.1M | -$67.2M | -$32.8M | -$27.1M | -$27.5M |
| Operating cash flow | -$93.4M | -$128.4M | -$145.1M | -$116.5M | -$108.2M | -$78.5M | -$46.4M | -$30.1M | -$26.5M | -$21.3M |
| Free cash flow | -$93.9M | -$128.7M | -$145.7M | -$117.2M | -$108.5M | -$78.5M | -$46.4M | -$30.1M | -$26.5M | -$21.4M |
| Diluted shares | 49.7M | 47.9M | 45.4M | 40.7M | 37.6M | 37.2M | 34.0M | 26.9M | 22.8M | 19.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $322.9M | $315.4M | $386.2M | $200.8M | $86.5M | $183.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $192.0M | $183.7M | $178.1M | $94.3M | $49.1M | $48.3M |
| Total assets | $689.8M | $568.5M | $588.2M | $331.5M | $87.8M | $186.1M |
| Total liabilities | $601.5M | $511.5M | $397.3M | $221.9M | $72.2M | $72.3M |
| Shareholders' equity | $88.3M | $57.0M | $191.0M | $109.6M | $15.6M | $113.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology